Clinical Trials Browser

Phase 3 × Withdrawn × Lymphoma, B-Cell, Marginal Zone × Clear all

NCT04796922 2022-07-18

To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302)

Phase 3 Withdrawn

Lymphoma, Follicular, Recurrence, Lymphoma, B-Cell, Marginal Zone

NCT02576275 2021-03-17

A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)

Phase 3 Withdrawn

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT00551239 2020-10-19

Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma

Phase 3 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone